ORGS (Orgenesis) Cyclically Adjusted PB Ratio: (As of Aug. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ORGS Orgenesis Inc ORGS
12 GF Score
Price $0.10
View Full Analysis

What is Orgenesis Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Orgenesis  (OTCPK:ORGS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Orgenesis Cyclically Adjusted PB Ratio Related Terms


Orgenesis Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Orgenesis's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orgenesis Cyclically Adjusted PB Ratio Chart

Orgenesis Annual Data
Trend Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.16 2.94 1.67 0.39 0.00

Orgenesis Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.63 0.46 0.34 0.00

ORGS vs ENDV, GBLX, OMGAQ: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Orgenesis's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orgenesis Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orgenesis's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Orgenesis's Cyclically Adjusted PB Ratio falls into.


ORGS
12GF Score
Orgenesis Inc ORGS
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orgenesis Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Orgenesis's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, Orgenesis's adjusted Book Value per Share data for the three months ended in Dec. 2024 was:

Adj_Book=Book Value per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-7.252/315.6050*315.6050
=-7.252

Current CPI (Dec. 2024) = 315.6050.

Orgenesis Quarterly Data

Book Value per Share CPI Adj_Book
201502 -7.775 234.722 -10.454
201505 -10.833 237.805 -14.377
201508 -12.817 238.316 -16.974
201511 -13.849 237.336 -18.416
201602 18.413 237.111 24.508
201605 16.822 240.229 22.100
201608 14.941 240.849 19.578
201611 13.141 241.353 17.184
201702 5.880 243.603 7.618
201705 9.978 244.733 12.868
201708 11.446 245.519 14.713
201711 14.309 246.669 18.308
201802 18.966 248.991 24.040
201805 19.399 251.588 24.335
201808 21.751 252.146 27.225
201811 18.963 252.038 23.746
201903 12.896 254.202 16.011
201906 9.997 256.143 12.318
201909 6.485 256.759 7.971
201912 3.393 256.974 4.167
202003 48.755 258.115 59.614
202006 39.943 257.797 48.900
202009 39.230 260.280 47.569
202012 21.709 260.474 26.304
202103 22.347 264.877 26.627
202106 20.930 271.696 24.313
202109 17.570 274.310 20.215
202112 15.852 278.802 17.945
202203 13.981 287.504 15.348
202206 12.793 296.311 13.626
202209 11.825 296.808 12.574
202212 10.787 296.797 11.471
202303 9.931 301.836 10.384
202306 8.418 305.109 8.708
202309 4.069 307.789 4.172
202312 -6.582 306.746 -6.772
202403 -8.071 312.332 -8.156
202406 -3.302 314.175 -3.317
202409 -5.009 315.301 -5.014
202412 -7.252 315.605 -7.252

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Orgenesis Business Description

Address 20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Octomera and Therapies. The company's therapies pipeline includes Immuno-Oncology, Viral Diseases, Metabolic & Autoimmune Diseases, Vascular & Musculoskeletal Diseases, and Kidney Disease.
12GF Score

Get the complete analysis for ORGS

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.10
Price